Alpha 2.0
Login Register
» Authors » Gretchen Tamms

Gretchen Tamms

Explore the profile of Gretchen Tamms including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 185
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
Pediatrics
Top 10 Co-Authors
Luwy Musey
Ron Dagan
Ulrike K Buchwald
Natalie Banniettis
Robert Lupinacci
Peter Richmond
Tina Sterling
Kara Bickham
Tulin Shekar
Alison Pedley
Published In
Vaccine
Clin Infect Dis
AIDS
Blood Adv
Pediatr Infect Dis J
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age
Omole T, Pelayo E, Weinberg A, Chalkias S, Endale Z, Tamms G, et al.
Vaccines (Basel) . 2025 Feb; 13(2). PMID: 40006738
Background/objectives: with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults. However, vaccination can be an effective preventative measure....
2.
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
Chapman T, Olarte L, Dbaibo G, Houston A, Tamms G, Lupinacci R, et al.
Expert Rev Vaccines . 2023 Dec; 23(1):137-147. PMID: 38111990
Introduction: is a causative agent of pneumonia and acute otitis media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 (V114) is a new 15-valent pneumococcal conjugate...
3.
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies
Chapman T, Patel S, Flores S, Xu S, Lupinacci R, Shi Y, et al.
Pediatr Infect Dis J . 2023 Aug; 42(11):1021-1028. PMID: 37566897
Background: Risk of invasive pneumococcal disease is 3-fold higher in preterm versus full-term infants. V114 is a 15-valent pneumococcal conjugate vaccine (PCV) containing the 13 serotypes in PCV13 plus 2...
4.
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
Wilck M, Cornely O, Cordonnier C, Velez J, Ljungman P, Maertens J, et al.
Clin Infect Dis . 2023 Jun; 77(8):1102-1110. PMID: 37338158
Background: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and...
5.
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study
Banniettis N, Horn M, Sadarangani M, Patel S, Greenberg D, Oberdorfer P, et al.
Pediatrics . 2023 Jun; 152(1). PMID: 37309607
Background And Objectives: Disease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines (PCVs) are well tolerated and effective at reducing pneumococcal disease...
6.
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A...
Hammitt L, Quinn D, Janczewska E, Pasquel F, Tytus R, Reddy K, et al.
Hum Vaccin Immunother . 2023 Mar; 19(1):2177066. PMID: 36864601
Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal...
7.
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, et al.
Vaccine . 2023 Jan; 41(5):1142-1152. PMID: 36621410
Background: Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine...
8.
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)
Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, et al.
Vaccine . 2022 Dec; 41(3):657-665. PMID: 36522265
Background: Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual...
9.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Quinn C, Wiedmann R, Jarovsky D, Lopez-Medina E, Rodriguez H, Papa M, et al.
Blood Adv . 2022 Nov; 7(3):414-421. PMID: 36383730
Sickle cell disease (SCD) is an inherited red blood cell disease that results in a multitude of medical complications, including an increased risk of invasive disease caused by encapsulated bacteria,...
10.
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants,...
Banniettis N, Wysocki J, Szenborn L, Phongsamart W, Pitisuttithum P, Ramet M, et al.
Vaccine . 2022 Sep; 40(44):6315-6325. PMID: 36150974
Background: Despite widespread use of pneumococcal conjugate vaccines (PCVs) in children, morbidity and mortality caused by pneumococcal disease (PD) remain high. In addition, many children do not complete their PCV...